Oncology & Oncosurgery

DPR_Radiotherapy_Unit (GR 29.08.2025) sanctions ₹24.50 Cr for a Linear Accelerator and radiation bunker on a turnkey basis. The LINAC is the cornerstone of radiotherapy — enabling external beam radiation for breast, head-neck, lung, cervical, and all solid tumours. GR is confirmed; CSR funding bypasses 2–3 years of government procurement cycles and activates the unit immediately.

Zero radiotherapy in Amravati public sector. All cancer patients needing radiation are referred to private hospitals (₹2–5 lakh/course) or Nagpur. Rural Vidarbha patients abandon incomplete referred radiation courses — a preventable cause of cancer mortality. GR sanctioned; deployment awaits procurement.

LINAC activates curative radiotherapy for 500–800 patients/year at zero cost under MJPJAY. First public-sector radiation therapy centre for five districts. Eliminates treatment abandonment for rural patients.

DPR_Radiotherapy_Unit (GR 29.08.2025) sanctions ₹7.50 Cr for a dedicated CT scanner for radiation treatment planning and virtual simulation. CT-based simulation is mandatory for all modern radiotherapy — without it, LINAC cannot be used safely or effectively. This is inseparable from LINAC activation.

No CT simulation infrastructure at RRSH. Radiation treatment planning without CT-simulation produces imprecise dose delivery — risk of both under-treatment (incomplete tumour control) and over-treatment (normal tissue damage).

Enables safe, image-guided, precise radiation planning for all LINAC patients. Mandatory companion to LINAC. Directly linked to radiotherapy unit activation.

DPR_Radiotherapy_Unit (GR 29.08.2025) sanctions ₹4.00 Cr for an HDR Brachytherapy system and dedicated bunker. HDR (High Dose Rate) Brachytherapy is essential for cervical, endometrial, and head-neck cancers — the dominant cancer burden in Vidarbha women. Without it, all patients needing internal radiation are referred out, with very low treatment completion rates.

Zero brachytherapy in Amravati public sector. Cervical cancer patients requiring HDR are referred to Nagpur or Pune. Distance and cost result in frequent treatment abandonment — with fatal consequences for rural women.

Curative-intent internal radiation for 200–300 gynaecological and head-neck cancer patients/year. Highest individual life-impact of any radiotherapy component for rural women.

DPR_BoneMarrowTransplant (DHS 2025-26 filing, sanction not yet confirmed) proposes a ₹35 Cr BMT unit at RRSH: Blood Centre expansion (₹4.87 Cr), Molecular Pathology Lab — HLA typing + MRD testing (₹25 Cr), 2× Apheresis machines (₹50 lakh), Day-Care Chemo + Patient Accommodation (₹4.60 Cr). This would be the first BMT unit in Vidarbha's public sector, specifically serving thalassaemia patients from Melghat tribal area and the five-district catchment.

No BMT capability in Amravati public sector. Thalassaemia patients — especially from tribal Melghat — requiring bone marrow transplant must travel to Mumbai or Pune (₹5–15 lakh, beyond reach of tribal families). No public-sector molecular pathology lab for HLA typing exists in the division.

Curative BMT for thalassaemia, aplastic anaemia, and selected haematological malignancies. 40–60 BMT procedures/year once operational. Molecular Path Lab serves 200+ haematology and oncology patients for precision diagnostics.

DPR_CriticalCare_Upgrade (DHS 2025-26, under state review) allocates ₹53.59 Cr to the Oncology + 10-bed ICU block: advanced endoscopic camera systems, harmonic cautery, colonoscopy equipment, operating microscope, and a fully equipped 10-bed Oncology ICU with ventilators and monitors. Enables complex oncosurgery and dedicated post-operative critical care within RRSH.

Complex oncosurgeries (oesophageal, colorectal, head-neck) limited by absence of advanced endoscopic and visualisation equipment. Post-surgical ICU monitoring managed in general critical care without dedicated oncology capacity.

Advanced oncosurgery capability + 10-bed Oncology ICU. Higher-complexity cancer resections feasible locally. Post-op mortality reduction through dedicated critical care monitoring for oncology patients.